# Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-02 14:01 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Executive Summary
Roche's drug candidate divarasib outperformed rival therapies in a Phase 3 trial for KRAS-driven lung cancer.

## Intelligence Brief
Roche has reported a successful Phase 3 study for its KRAS G12C inhibitor, divarasib. The late-stage trial focused on non-small cell lung cancer (NSCLC), where the drug candidate beat existing therapies in head-to-head comparisons.


Coverage from the Wall Street Journal, STAT, and Fierce Biotech emphasizes that Roche's candidate outperformed rivals from Amgen and BMS. Endpoints News and FirstWord PHARMA characterize the results as a win over existing KRAS G12C inhibitors.


Future developments depend on the drug setting a new standard for treating KRAS-driven lung cancer following these trial results.

## Verified Facts & Key Claims
### What is the name of the drug candidate?
The drug candidate is called divarasib.

### Which companies did Roche's drug compete against in the study?
The study involved head-to-head comparisons against rivals from Amgen and BMS.

### What specific condition is the drug designed to treat?
It is a KRAS G12C inhibitor used for KRAS-driven non-small cell lung cancer (NSCLC).

## Key People, Organizations & Locations
Phase, Roche, KRAS, Roche Lung-Cancer Drug Candidate Beats Existing Therapies, Late-Stage Trial, KRAS G12C, Amgen BMS, KRAS-driven

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Endpoints News | Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study | 2026-07-02 05:50 | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxOOENWdm9tdV92WmtpRjdjM1FwSnl5RjJMOHRBX3hIVTZSZkdnaGUtUTVyT3g5Z3R4dUNTU2stVzF5VzEtbW9yb3hteUNqQzNxeHBfeVNrYjFFc3djbjFhSFdfQlctVk03ZDBhcm11X1Q1WUQ4NTN0bjNZZlVMVnZveGNQWC02SWtNTjFnVmY5Y1c1eTV0?oc=5) |
| Fierce Biotech | Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS | 2026-07-02 05:50 | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxNbzNZMndOb05KcWRYWThodXFOejBzTzZFUFZKQnBZVERfWklDbDRwMGxneERJWHFzODJIQ1h3Wmk1UDlkeFRtclQ0SUJOd2hzZVZFdWpBQ3pOb3RsRVU3Z0NnVU5vaTNTTms0U1oySVNQUk9oS3djcU8xX1JhYXl1dWVjd2NuVU5aQl9oZzFubElZMUk1X1ZWZzBlUUdVMWk0ZkhOYjZrcHB2dmtjYjRLb3FTdk8?oc=5) |
| STAT | Roche drug sets new standard for KRAS-driven lung cancer | 2026-07-02 05:50 | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxOOW9LYVlIZmVQcDRIWV93dWFKVVFoQkl6WkFIZEFNZUstZUR0QTNuZHJtN3RTNmxqSTZkUDJiQmNRSVpBVkc1TnExU2k4bExfTmlEVmtoRjRfNkxmX1hITlhvcUZLejJ2clhnQVg1MkhJVnBaWmdSMUlzbnVRYjBRREFoSUlmUDRfdHhxS2s5MVdwanR5SHpYUjd5YkIyZm5Eek9RZllFQ3lVUQ?oc=5) |
| FirstWord PHARMA | Roche's divarasib bests KRAS G12C rivals in late-stage NSCLC study | 2026-07-02 05:50 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE9Pa1VfazJGc25VRE9ITG94Rkh3cDF1OUZ4ZGdNMGdmSWdjdDJBbC1hZ2M4OFFtT0NSMEZLNGZSeGYwcm5FNkYtemg4Y1RKRnpia3Zv?oc=5) |
| WSJ | Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial | 2026-07-02 05:50 | [Source Link](https://news.google.com/rss/articles/CBMivAFBVV95cUxQVXdHMWRqWUJFSEhLakJJNldOZkZjV2liY25aWGdCOFJmd1FJRzlYNmhwMzY3WWtBYkh2M3FldTRrdHFTbkZ4dGwtOW04NTRmbjktdXJwNmw5OUllWE1DZXYxVV91MGp0V21mSVRnUjFFS2pFTHhJS3FqLXZ0N2lPeklYR3NCaVR4MmdZRDFWWHVUWE5aSUJlN1JSbUpSZVJvS1lTQlA1UnhyZ2NfTVVqNzRjUFgtUU83d09vNg?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-02/roche-lung-cancer-drug-candidate-beats-existing-therapies-in-late-stage-trial*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*